ReviewInternational journal of nanomedicine2018
Nanotechnology, an alternative with promising prospects and advantages for the treatment of cardiovascular diseases.
Review in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Targeted and safe delivery of colchicine via polymeric nanocarriers for potential atherosclerosis therapy with in vitro and in vivo evaluation.Scientific reports · 2025Article
- Using nanotechnology for the diagnosis and treatment of coronary artery disease: a narrative review.The British journal of cardiology · 2025Article
- A Spotlight on PLGA-based Nanoparticles: Pioneering a New Era in the Therapeutics of Cardiovascular Disorders.Current pharmaceutical design · 2025Review
- Advances in nanotechnological approaches for the detection of early markers associated with severe cardiac ailments.Nanomedicine (London, England) · 2024Review
- Advances in Nano-Functional Materials in Targeted Thrombolytic Drug Delivery.Molecules (Basel, Switzerland) · 2024Review
- Review
- Liposome-Derived Nanosystems for the Treatment of Behavioral and Neurodegenerative Diseases: The Promise of Niosomes, Transfersomes, and Ethosomes for Increased Brain Drug Bioavailability.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Attenuation of Hyperlipidemia by Medicinal Formulations ofBioengineering (Basel, Switzerland) · 2023Review
- Investigation of the pharmacological effect and mechanism of mountain-cultivated ginseng and garden ginseng in cardiovascular diseases based on network pharmacology and zebrafish experiments.Frontiers in pharmacology · 2022Article
- A Revolutionary Blueprint for Mitigation of Hypertension via Nanoemulsion.BioMed research international · 2022Review
- Neuregulin-1, a potential therapeutic target for cardiac repair.Frontiers in pharmacology · 2022Review
- Nano drugs delivery system: A novel promise for the treatment of atrial fibrillation.Frontiers in cardiovascular medicine · 2022Review
- Stabilization by Nano Spray Dryer of Pioglitazone Polymeric Nanosystems: Development, In Vivo, Ex Vivo and Synchrotron Analysis.Pharmaceutics · 2021Article
- Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine.Pharmaceutics · 2021Review
- Designing S100A9-Targeted Plant Virus Nanoparticles to Target Deep Vein Thrombosis.Biomacromolecules · 2021Article
- Nanomaterials as Novel Cardiovascular Theranostics.Pharmaceutics · 2021Review
- Review
- Innovative Therapies and Nanomedicine Applications for the Treatment of Alzheimer's Disease: A State-of-the-Art (2017-2020).International journal of nanomedicine · 2020Review
- Targeting Plasmids to Limit Acquisition and Transmission of Antimicrobial Resistance.Frontiers in microbiology · 2020Review
- Nanodelivery of Natural Antioxidants: An Anti-aging Perspective.Frontiers in bioengineering and biotechnology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) are one of the most important causes of mortality and affecting the health status of patients. At the same time, CVDs cause a huge health and economic burden to the whole world. Although a variety of therapeutic drugs and measures have been produced to delay the progress of the disease and improve the quality of life of patients, most of the traditional therapeutic strategies can only cure the symptoms and cannot repair or regenerate the damaged ischemic myocardium. In addition, they may bring some unpleasant side effects. Therefore, it is vital to find and explore new technologies and drugs to solve the shortcomings of conventional treatments. Nanotechnology is a new way of using and manipulating the matter at the molecular scale, whose functional organization is measured in nanometers. Because nanoscale phenomena play an important role in cell signal transduction, enzyme action and cell cycle, nanotechnology is closely related to medical research. The application of nanotechnology in the field of medicine provides an alternative and novel direction for the treatment of CVDs, and shows excellent performance in the field of targeted drug therapy and the development of biomaterials. This review will briefly introduce the latest applications of nanotechnology in the diagnosis and treatment of common CVDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.